Voyager Therapeutics (NASDAQ:VYGR)‘s stock had its “buy” rating reiterated by analysts at BTIG Research in a research note issued to investors on Sunday, March 11th. They currently have a $32.00 price target on the stock. BTIG Research’s price target suggests a potential upside of 52.02% from the company’s current price.
Other equities analysts have also recently issued reports about the stock. BidaskClub upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, January 5th. Canaccord Genuity set a $26.00 price target on shares of Voyager Therapeutics and gave the stock a “buy” rating in a report on Wednesday, November 15th. Zacks Investment Research raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 6th. Wedbush reissued an “outperform” rating and issued a $26.00 price target (up previously from $22.00) on shares of Voyager Therapeutics in a report on Monday, November 20th. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $28.00 price target on shares of Voyager Therapeutics in a report on Tuesday, November 28th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $29.73.
Shares of Voyager Therapeutics (NASDAQ:VYGR) traded down $0.77 during midday trading on Friday, reaching $21.05. 166,201 shares of the company’s stock traded hands, compared to its average volume of 450,396. Voyager Therapeutics has a twelve month low of $8.10 and a twelve month high of $31.91. The firm has a market cap of $702.75, a PE ratio of -7.98 and a beta of 2.37.
Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Wednesday, March 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.32. Voyager Therapeutics had a negative net margin of 697.03% and a negative return on equity of 63.18%. The firm had revenue of $6.35 million during the quarter, compared to analysts’ expectations of $5.81 million. sell-side analysts forecast that Voyager Therapeutics will post -2.54 earnings per share for the current year.
In related news, insider Bernard Ravina sold 2,451 shares of the company’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $25.16, for a total value of $61,667.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Dinah Ph.D. Sah sold 15,623 shares of the company’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $30.00, for a total transaction of $468,690.00. Following the completion of the sale, the insider now directly owns 140,872 shares of the company’s stock, valued at approximately $4,226,160. The disclosure for this sale can be found here. Insiders have sold 24,155 shares of company stock valued at $634,595 in the last ninety days. Insiders own 8.00% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in VYGR. Thompson Davis & CO. Inc. grew its holdings in shares of Voyager Therapeutics by 67.7% in the fourth quarter. Thompson Davis & CO. Inc. now owns 7,485 shares of the company’s stock valued at $124,000 after purchasing an additional 3,021 shares during the period. MetLife Investment Advisors LLC acquired a new position in Voyager Therapeutics in the fourth quarter valued at about $128,000. Goldman Sachs Group Inc. lifted its position in Voyager Therapeutics by 8.9% in the second quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock valued at $153,000 after buying an additional 1,399 shares during the last quarter. Teachers Advisors LLC lifted its position in Voyager Therapeutics by 24.7% in the second quarter. Teachers Advisors LLC now owns 25,685 shares of the company’s stock valued at $230,000 after buying an additional 5,081 shares during the last quarter. Finally, California State Teachers Retirement System lifted its position in Voyager Therapeutics by 8.4% in the second quarter. California State Teachers Retirement System now owns 25,811 shares of the company’s stock valued at $231,000 after buying an additional 2,000 shares during the last quarter. 80.03% of the stock is owned by hedge funds and other institutional investors.
WARNING: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/03/19/voyager-therapeutics-vygr-given-buy-rating-at-btig-research.html.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.